WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive... Read More

Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals Additional preclinical data demonstrate INDUKINE TM molecules’ anti-tumor potency with distinct immune activation profiles across four cytokines WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or... Read More

Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual Meeting Monotherapy and combination expansion arms open and enrolling in ongoing Phase 1/1b clinical trial of WTX-124; initial efficacy data from monotherapy expansion arms anticipated in the first half of 2025 Introduced WTX-921, a promising new development candidate and... Read More

WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced the addition of WTX-921, a novel IL-10 INDUKINE development... Read More

WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 39th... Read More

WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs,... Read More

Positive data from ongoing Phase 1/1b clinical trial of WTX-124 presented at American Society of Clinical Oncology (ASCO) Annual Meeting Encouraging signs of clinical activity at tolerable doses disclosed from ongoing Phase 1 clinical trial of WTX-330 Updated data on WTX-124 in combination with pembrolizumab and opening of expansion arms anticipated in the second half of 2024 Update on WTX-330 dose escalation and expansion... Read More

Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical data for rhIL-12 Early WTX-330 dose-escalation data demonstrated encouraging clinical activity and evidence of immune biomarker activity including an unconfirmed partial response in a metastatic melanoma patient Expansion arms open to... Read More

WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete response Monotherapy recommended dose for expansion selected and expansion arms open for enrollment Preliminary data on WTX-124 administered to patients in... Read More

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs,... Read More

Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers Preliminary data on WTX-124 administered in combination with pembrolizumab show similar tolerability to WTX-124 monotherapy Additional details and data post abstract cut-off date to be presented at ASCO Company to host webcast to... Read More

Company to present an update of its ongoing monotherapy and combination Phase 1/1b trial of WTX-124 in advanced or metastatic solid tumors at ASCO Company plans to present interim, first-in-human clinical data from the ongoing Phase 1 trial of WTX-330 in the second quarter of 2024 Multiple presentations of preclinical data demonstrate the potential of the PREDATOR TM platform, including in immunology-based diseases Company... Read More

Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for... Read More

First Data Demonstrating Application of PREDATOR™ Platform in Immune-Mediated Diseases WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced a poster presenting preclinical data characterizing conditionally-activated IL-10 INDUKINE molecules for the treatment of colitis in animal models, a novel approach leveraging its PREDATOR™ protein... Read More

WTX-518, a conditionally activated IL-18 INDUKINE TM molecule that resists suppression by IL-18BP, led to complete tumor regressions in preclinical models WTX-712, a conditionally activated IL-21 INDUKINE TM molecule has potent antitumor activity in preclinical models with a differentiated immune activation mechanism WATERTOWN, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or... Read More

WATERTOWN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the publication of an abstract for an upcoming poster presentation at IMMUNOLOGY TM 2024, the annual... Read More

Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024 WTX-124 recommended dose for expansion (RDE), initiation of monotherapy dose expansion arms and initial combination dose-escalation data also expected in the first half of 2024 Preliminary data from Phase 1 clinical trial of WTX-330 expected in the second quarter of 2024 Updated... Read More

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs,... Read More

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the publication of abstracts for upcoming poster presentations at the American Association for... Read More

Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINE TM programs anticipated in 2024 WTX-124: updated interim monotherapy dose-escalation data and initial combination dose escalation data from Phase 1/1b clinical trial expected in 1H 2024 WTX-330: preliminary dose-escalation data from Phase 1 clinical trial expected in 2Q 2024 Updated cash guidance provides runway... Read More

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors. “Mike is a... Read More

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs,... Read More

Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity Safety data indicate WTX-124 is generally well tolerated through cohort 4 (12 mg), with a wide therapeutic index supportive of continued dose escalation Additional interim WTX-124 monotherapy data and recommended dose for expansion... Read More

Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors relapsed or refractory to standard of care therapy, including two patients with ongoing unconfirmed partial responses (uPR) in the highest dose tested to date, cohort 4 (12 mg) Safety data indicate WTX-124 is generally well-tolerated through cohort 4 with no... Read More

Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor activity to be described in poster presentation. Additional posters representing an expansive body of data demonstrating the potential of Werewolf’s PREDATOR™ platform and INDUKINE™ product candidates will also be presented. Company to host conference call... Read More

Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meeting Company to present interim first-in-human clinical data from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 WATERTOWN, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative... Read More

WATERTOWN, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it will host a virtual R&D Event on Monday, September 18, 2023, at 10:00 am ET. The event will... Read More

WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will participate in the following upcoming investor conferences in the month of... Read More

Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 Phase 1 clinical trial for IL-12 INDUKINE WTX-330 progressing in patients with advanced or metastatic solid tumors or lymphoma WATERTOWN, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the... Read More

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present a company overview at 4:00 PM ET on June 8 at the Jefferies Healthcare... Read More

Progressing Phase 1/1b clinical trial for IL-2 INDUKINE WTX-124 in advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 Progressing Phase 1 clinical trial for IL-12 INDUKINE WTX-330 in patients with advanced or metastatic solid tumors or lymphoma; preclinical data published in Cancer Immunology Research First preclinical data for new candidate... Read More

WATERTOWN, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will participate at the following conferences in the month of May: Bank of America... Read More

WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology Research Online First of preclinical data for mWTX-330, a systemically delivered Interleukin-12 (IL-12) INDUKINE TM molecule. The article,... Read More

Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumors Dosed first patient in Phase 1 clinical trial evaluating IL-12 INDUKINE WTX-330 in patients with advanced or metastatic solid tumors or lymphoma Nominated WTX-712, a conditionally active IL-21 INDUKINE molecule targeting oncology indications; preclinical data to... Read More

WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the publication of abstracts for upcoming poster presentations at the American Association for... Read More

CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the publication of an abstract summarizing an upcoming poster presentation at the American... Read More

WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the safety, tolerability, and clinical activity of WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma Second clinical stage program of a new class of systemically delivered, conditionally activated INDUKINE™ therapeutics developed by Werewolf WATERTOWN, Mass.,... Read More

WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will present virtually at 8:40AM ET on February 16 th at the SVB Securities Global Biopharma Conference, taking place February 14 th -16 th , 2023. A link to the live webcast for the conference will be available at... Read More